Institute Of Cancer Research, United Kingdom

This study tests a new drug called paxalisib combined with standard chemotherapy (temozolomide) in people with aggressive brain tumours like glioblastoma. The goal is to see if the combination is safe and can slow tumour growth or improve survival. About 64 participants will take…

This study tests whether adding a new drug called SX-682 to the existing drug apalutamide can help control metastatic castration-resistant prostate cancer (mCRPC) in men. The trial involves 78 participants and will check for safety, the right dose, and signs that the cancer is sh…

This trial tests two drugs, avutometinib and defactinib, alone or with a third drug (temozolomide), in people with aggressive brain tumours like glioblastoma. The goal is to see if the combination is safe and can shrink tumours or slow their growth. About 182 adults with recurren…

This study tests whether adding a combination of antibiotics to the standard drug enzalutamide can safely improve treatment for men with metastatic castration-resistant prostate cancer (mCRPC). About 39 participants will receive two weeks of amoxicillin and metronidazole, then tw…

This study tests if injecting a very dilute hydrogen peroxide solution into breast tumors can make standard radiotherapy work better. It is for people with advanced or returning breast cancer. The treatment involves a few injections during radiation, and early results from Japan …

This early-phase trial tests a new drug (ASTX660) combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors, including triple-negative breast cancer and cervical cancer. The goal is to see if the combination is safe and can help the immune system recogni…

This study aims to see if a type of PET-CT scan (FCH-PET-CT) is better than standard scans (bone scan and MRI/CT) at finding cancer that has spread outside the pelvis in men with prostate cancer who have specific gene mutations (like BRCA). About 50 men with these mutations will …

This study is testing a new saliva-based DNA test called i4i PRODICT® that estimates a man's future risk of prostate cancer. Researchers want to see if men from Black, South Asian, and White backgrounds are willing to take the test and find it acceptable. The goal is to enroll 1,…

This study looks at whether a genetic test can help assess prostate cancer risk in men who either have the disease or are at high risk. Researchers will analyze DNA from 3,000 men to find rare and common genetic changes linked to prostate cancer. The goal is to see if this inform…

This study follows over 4,000 men with prostate cancer, some who carry rare gene mutations (like BRCA) and some who don't. Researchers will compare survival and cancer progression between the groups using medical records and tumor samples. The goal is to learn how these genes aff…

This study follows 200 men with prostate cancer who are on active surveillance (monitoring instead of immediate treatment). It compares those with higher genetic risk to those with average risk to see how their cancer changes over time. The goal is to learn whether genetic factor…